Search

Displaying results 2431 - 2440 of 10000 in total
  1. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion. … Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).

  2. Drug

    ReN001

    go.drugbank.com/drugs/DB05236
    Investigational

    ReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke. … ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the treatment of stroke in humans

  3. Drug

    Salmeterol

    go.drugbank.com/drugs/DB00938
    ApprovedInvestigational

    [A190459] Salmeterol was first described in the literature in 1988.[A190477] Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. … Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.

  4. Drug

    Plasma protein fraction (human)

    go.drugbank.com/drugs/DB13968
    ApprovedInvestigational

    [L2262] The proteins in PPFh are stabilized with sodium caprylate and acetyltryptophan and it contains some electrolytes such as sodium, potassium and chloride.[L2261] … It is also stated that no more than 1% of the total protein should be gamma globulin.[L2260] PPFh is a sterile, frozen solution of solvent/detergent treated human plasma.

  5. Drug

    Diethylpropion

    go.drugbank.com/drugs/DB00937
    ApprovedIllicitInvestigational

    A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. … It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)

    International brands: Linea
  6. Drug

    Droloxifene

    go.drugbank.com/drugs/DB15641
    Experimental

    Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity … It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Ocrelizumab

    go.drugbank.com/drugs/DB11988
    ApprovedInvestigational

    It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. … In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a].

  8. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    [A229273] Loss-of-function mutations in _ANGPTL3_ have been noted to result in hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with … Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.

  9. Drug

    Ephedra sinica root

    go.drugbank.com/drugs/DB01363
    ApprovedNutraceutical

    The drug is still sold in Canada in OTC formulations for respiratory conditions associated with bronchial asthma. … The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 due to the risk for adverse effects and a lack of evidence for

    Products: Fyto-HB I- Cap 10mg
  10. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.